A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy.
Li H, Zhou K, Wang K, Cao H, Wu W, Wang Z, Dai Z, Chen S, Peng Y, Xiao G, Luo P, Zhang J, Liu Z, Cheng Q, Zhang H.
Li H, et al. Among authors: zhang j, zhang h.
Front Immunol. 2022 Dec 22;13:1040289. doi: 10.3389/fimmu.2022.1040289. eCollection 2022.
Front Immunol. 2022.
PMID: 36660546
Free PMC article.